This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Levine, J. H. Articles by Kadish, A. H. Search for Related Content PubMed PubMed Citation Articles by Levine, J. H. Articles by Kadish, A. H.

Circulation, Vol 80, 1063-1069, Copyright © 1989 by American Heart Association

ARTICLES

Mechanisms and risk factors for proarrhythmia with type Ia compared with Ic antiarrhythmic drug therapy

JH Levine, J Morganroth and AH Kadish
Division of Cardiology, St. Francis Hospital and Cardiac Center, Roslyn, New York 11576.

Proarrhythmia defined as the exacerbation of existing arrhythmias or the genesis of new arrhythmias de novo may result from any antiarrhythmic agent. The two general clinical syndromes of sustained arrhythmias that result appear to have distinct clinical properties that are consistent with the proposed basic mechanisms of arrhythmogenesis. Torsades de points occurs most commonly in association with administration of type Ia antiarrhythmic agents and has characteristics most consistent with triggered activity mediated by early after depolarization. Conversely, incessant, sustained, monomorphic, wide complex ventricular tachycardia occurs most commonly in association with type Ic antiarrhythmic agents and has characteristics most consistent with incessant reentry. These general subdivisions are probably oversimplified, and in fact, much overlap likely exists. In addition, these proposed mechanisms may not apply to other forms of proarrhythmia such as an increased frequency of isolated ventricular premature couplets or repetitive forms. Furthermore, proarrhythmia may also occur during treatment of supraventricular arrhythmias; although some of these described syndromes are consistent with incessant reentry, the clinical syndromes are not sufficiently defined to better characterize potential mechanisms. Further investigation, therefore, is needed to better define the mechanisms in question, but the mechanisms proposed in this article help to provide a rational approach toward understanding and dealing with clinical proarrhythmia.

This article has been cited by other articles:

				A. A. Grace and A. J. Camm Quinidine N. Engl. J. Med., January 1, 1998; 338(1): 35 - 45. [Full Text] [PDF]

				Y.-G. Li and S. H. Hohnloser Clinical Review : Update on Atrial Fibrillation: Restoration of Sinus Rhythm or Ventricular Rate Control? Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1998; 3(2): 185 - 194. [Abstract] [PDF]

				J. A. Reiffel Data-driven Decisions: The Importance of Clinical Trials in Arrhythmia Management Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1996; 1(1): 79 - 88. [Abstract] [PDF]

				S. Ranger and S. Nattel Determinants and Mechanisms of Flecainide-Induced Promotion of Ventricular Tachycardia in Anesthetized Dogs Circulation, September 1, 1995; 92(5): 1300 - 1311. [Abstract] [Full Text]

				J. Coromilas, A. E. Saltman, B. Waldecker, S. M. Dillon, and A. L. Wit Electrophysiological Effects of Flecainide on Anisotropic Conduction and Reentry in Infarcted Canine Hearts Circulation, April 15, 1995; 91(8): 2245 - 2263. [Abstract] [Full Text]

				M. Restivo, H. Yin, E. B. Caref, A. I. Patel, G. Ndrepepa, M. J. Avitable, M. A. Assadi, N. Isber, and N. El-Sherif Reentrant Arrhythmias in the Subacute Infarction Period : The Proarrhythmic Effect of Flecainide Acetate on Functional Reentrant Circuits Circulation, February 15, 1995; 91(4): 1236 - 1246. [Abstract] [Full Text]

				S. H. Hohnloser and R. L. Woosley Sotalol N. Engl. J. Med., July 7, 1994; 331(1): 31 - 38. [Full Text]

				R. R. Makkar, B. S. Fromm, R. T. Steinman, M. D. Meissner, and M. H. Lehmann Female Gender as a Risk Factor for Torsades de Pointes Associated With Cardiovascular Drugs JAMA, December 1, 1993; 270(21): 2590 - 2597. [Abstract] [PDF]

				R. Damle, J. Levine, J. Matos, S. Greenberg, R. Brooks, W. Frumkin, J. Goldberger, and A. H. Kadish Efficacy and Risks of Moricizine in Inducible Sustained Ventricular Tachycardia Ann Intern Med, March 1, 1992; 116(5): 375 - 381. [Abstract] [PDF]